Aberrant skipping of coding exons in CD19 and CD22 compromises the response to
immunotherapy in B-cell
malignancies. Here, we showed that the MS4A1 gene encoding human CD20 also produces several
messenger RNA (
mRNA) isoforms with distinct
5' untranslated regions. Four variants (V1-4) were detected using
RNA sequencing (
RNA-seq) at distinct stages of normal B-cell differentiation and B-lymphoid
malignancies, with V1 and V3 being the most abundant. During B-cell activation and
Epstein-Barr virus infection, redirection of splicing from V1 to V3 coincided with increased CD20 positivity. Similarly, in
diffuse large B-cell lymphoma, only V3, but not V1, correlated with CD20
protein levels, suggesting that V1 might be translation-deficient. Indeed, the longer V1
isoform contained upstream open reading frames and a stem-loop structure, which cooperatively inhibited polysome recruitment. By modulating CD20
isoforms with splice-switching
morpholino oligomers, we enhanced CD20 expression and anti-CD20 antibody
rituximab-mediated cytotoxicity in a panel of B-cell lines. Furthermore, reconstitution of CD20-knockout cells with V3
mRNA led to the recovery of CD20 positivity, whereas V1-reconstituted cells had undetectable levels of CD20
protein. Surprisingly, in vitro CD20-directed
chimeric antigen receptor T cells were able to kill both V3- and V1-expressing cells, but the bispecific T-cell engager mosunetuzumab was only effective against V3-expressing cells. To determine whether CD20 splicing is involved in
immunotherapy resistance, we performed
RNA-seq on 4 postmosunetuzumab
follicular lymphoma relapses and discovered that in 2 of them, the downregulation of CD20 was accompanied by a V3-to-V1 shift. Thus, splicing-mediated mechanisms of
epitope loss extend to CD20-directed
immunotherapies.